Featured Research

from universities, journals, and other organizations

Crucial step in AIDS virus maturation simulated for first time

Date:
December 4, 2012
Source:
IMIM (Hospital del Mar Medical Research Institute)
Summary:
Bioinformaticians in Spain have used molecular simulation techniques to explain a specific step in the maturation of the HIV virions, i.e., how newly formed inert virus particles become infectious, which is essential in understanding how the virus replicates. These results could be crucial to the design of future antiretrovirals.

HIV protease cutting the poly-protein chain.
Credit: IMIM

Using computational techniques, researchers in Spain have shown how a protein responsible for the maturation of the virus releases itself to initiate infection.

Bioinformaticians at IMIM (Hospital del Mar Medical Research Institute) and UPF (Pompeu Fabra University) have used molecular simulation techniques to explain a specific step in the maturation of the HIV virions, i.e., how newly formed inert virus particles become infectious, which is essential in understanding how the virus replicates. These results, which have been published in the latest edition of PNAS, could be crucial to the design of future antiretrovirals.

HIV virions mature and become infectious as a result of the action of a protein called HIV protease. This protein acts like a pair of scissors, cutting the long chain of connected proteins that form HIV into individual proteins that will form the infectious structure of new virions. According to the researchers of the IMIM-UPF computational biophysics group, "One of the most intriguing aspects of the whole HIV maturation process is how free HIV protease, i.e. the 'scissors protein,' appears for the first time, since it is also initially part of the long poly-protein chains that make up new HIV virions."

Using ACEMD a software for molecular simulations and a technology known as GPUGRID.net, Gianni De Fabritiis' group has demonstrated that the first "scissors proteins" can cut themselves out from within the middle of these poly-protein chains. They do this by binding one of their connected ends (the N-terminus) to their own active site and then cutting the chemical bond that connects them to the rest of the chain. This is the initial step of the whole HIV maturation process. If the HIV protease can be stopped during the maturation process, it will prevent viral particles, or virions, from reaching maturity and, therefore, from becoming infectious.

This work was performed using GPUGRID.net, a voluntary distributed computing platform that harnesses the processing power of thousands of NVIDIA GPU accelerators from household computers made available by the public for research purposes. It's akin to accessing a virtual supercomputer. One of the benefits of GPU acceleration is that it provides computing power that is around 10 times higher than that generated by computers based on CPUs alone. It reduces research costs accordingly by providing a level computational power that previously was only available on dedicated, multi-million dollar supercomputers.

Researchers use this computing power to process large numbers of data and generate highly complex molecular simulations. In this specific case, thousands of computer simulations have been carried out, each for hundreds of nanoseconds (billionths of a second) for a total of almost a millisecond.

According to researchers, this discovery in the HIV maturation process provides an alternative approach in the design of future pharmaceutical products based on the use of these new molecular mechanisms. For now, this work provides a greater understanding of a crucial step in the life cycle of HIV, a virus that directly attacks and weakens the human immune system, making it vulnerable to a wide range of infections, and which affects millions of people around the world.


Story Source:

The above story is based on materials provided by IMIM (Hospital del Mar Medical Research Institute). Note: Materials may be edited for content and length.


Journal Reference:

  1. S. K. Sadiq, F. Noe, G. De Fabritiis. Kinetic characterization of the critical step in HIV-1 protease maturation. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1210983109

Cite This Page:

IMIM (Hospital del Mar Medical Research Institute). "Crucial step in AIDS virus maturation simulated for first time." ScienceDaily. ScienceDaily, 4 December 2012. <www.sciencedaily.com/releases/2012/12/121204081320.htm>.
IMIM (Hospital del Mar Medical Research Institute). (2012, December 4). Crucial step in AIDS virus maturation simulated for first time. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/12/121204081320.htm
IMIM (Hospital del Mar Medical Research Institute). "Crucial step in AIDS virus maturation simulated for first time." ScienceDaily. www.sciencedaily.com/releases/2012/12/121204081320.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins